Literature DB >> 21107181

Endovascular treatment of symptomatic intracranial arterial stenosis: six-year experience in a single-center series of 42 consecutive patients with acute and mid-term results.

Vincent Costalat1, Igor Lima Maldonado, Jean-Baptiste Zerlauth, Nicolas Menjot, Carlos Riquelme, Paolo Machi, Jean-François Vendrell, Alain Bonafé.   

Abstract

BACKGROUND: The limitations of the medical management of symptomatic intracranial arterial stenosis encourage the development of new therapeutic strategies such as intracranial stenting.
OBJECTIVE: To report and analyze the results of a series of 42 patients treated with 3 different endovascular techniques: isolated angioplasty, balloon-expandable coronary stents, and the Wingspan self-expandable intracranial stent system.
METHODS: Forty-two patients presenting with symptomatic intracranial arterial stenosis were treated with one of these techniques. Computed tomography angiography was performed 6 months after the procedure, and the clinical neurological statuses were categorized using the modified Rankin Scale and the National Institutes of Health Stroke Scale.
RESULTS: A total of 42 lesions were treated: 9 with isolated angioplasty, 14 with balloon-expandable coronary stents, and 19 with Wingspan self-expandable intracranial stents. The mean patient age was 62.9 years, and the mean arterial diameter stenosis was 73.9%. Technical success was achieved in 97.6% of the patients. The overall incidence of procedural complications was 21.4%, and the postoperative permanent morbidity/mortality rate was 7.1%. There were 3 cases of in-stent thrombosis (1 fatal) and 5 cases of asymptomatic restenosis (11.9%), 3 in the isolated angioplasty group and 2 in the Wingspan self-expandable intracranial stent group (mean follow-up 20.4 months). The rate of restenosis was higher in the angioplasty group (33%) than in the coronary (0%) and Wingspan stent (10.5%) groups.
CONCLUSION: Endovascular treatment of symptomatic intracranial stenosis has significant overall morbidity and mortality rates. Nevertheless, the very critical natural history of severe refractory lesions and the relatively favorable postoperative evolution suggest that it should be considered the first alternative strategy in cases in which medical therapy has failed.

Entities:  

Mesh:

Year:  2010        PMID: 21107181     DOI: 10.1227/NEU.0b013e3181f7ef1f

Source DB:  PubMed          Journal:  Neurosurgery        ISSN: 0148-396X            Impact factor:   4.654


  3 in total

Review 1.  Off-label use of drugs and devices in the neuroendovascular suite.

Authors:  M M Abdihalim; A E Hassan; A I Qureshi
Journal:  AJNR Am J Neuroradiol       Date:  2013-03-21       Impact factor: 3.825

Review 2.  Endovascular Therapy for Symptomatic Intracranial Artery Stenosis: a Systematic Review and Network Meta-analysis.

Authors:  Tao Wang; Kun Yang; Xiao Zhang; Jichang Luo; Ran Xu; Xue Wang; Yutong Yang; Xuesong Bai; Yan Ma; Yuxiang Yan; Liqun Jiao
Journal:  Transl Stroke Res       Date:  2022-02-12       Impact factor: 6.800

3.  Balloon-expandable stents for treatment of symptomatic middle cerebral artery stenosis: Clinical outcomes during long-term follow-up.

Authors:  Sung Hyun Baik; Hyo Sung Kwak; Gyung Ho Chung; Seung Bae Hwang
Journal:  Interv Neuroradiol       Date:  2018-07-10       Impact factor: 1.610

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.